Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

NCT05321147 is registered in ClinicalTrials.gov with Innate Pharma as lead sponsor.

NCT NCT05321147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05321147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase Ib Trial Evaluating the Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2
Lead sponsor
Innate Pharma
Phase
Phase 1
Overall status
Completed
Start date
March 17, 2022
Completion date
February 8, 2024
Enrollment
20 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

peripheral t cell lymphoma